Advertisement

Pharmaceutisch Weekblad

, Volume 7, Issue 6, pp 237–244 | Cite as

Cisplatin: a review of clinical applications and renal toxicity

  • Dirk Th. Sleijfer
  • Sijtze Meijer
  • Nanno H. Mulder
Review Articles

Abstract

In reviewing the literature about the clinical application ofcis-diamminedichloroplatinum(II) (cisplatin) it can be concluded that the availability of cisplatin has been an important advance in cancer chemotherapy; especially in patients with disseminated testicular carcinoma and ovarian cancer cisplatin-based combinations are the first choice treatment. Our own investigations of the nature of the main form of toxicity of cisplatin, the nephrotoxicity, are mentioned and methods of its prevention are summarized.

Keywords

Public Health Carcinoma Internal Medicine Ovarian Cancer Clinical Application 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Einhorn LH, Donohue J.Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular carcinoma. Ann Intern Med 1977:87:293–8.PubMedGoogle Scholar
  2. 2.
    Stoter G, Sleijfer DTh, Vendrik CPJ, et al. Combination chemotherapy withcis-diamminedichloroplatinum, vinblastine and bleomycin in advanced testicular non-seminoma. Lancet 1979;1:941–5.PubMedGoogle Scholar
  3. 3.
    Stoter G, Vendrik CPJ, Struyvenberg A, et al. The 5-year survival of patients with disseminated non-seminomatous testicular cancer treated with cisplatin, vinblastine and bleomycin. Cancer 1984:54:1521–4.PubMedGoogle Scholar
  4. 4.
    Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular carcinoma. N Engl J Med 1981;305:727–31.PubMedGoogle Scholar
  5. 5.
    Williams SD, Einhorn LH. Etoposide salvage therapy for refractory germ cell tumours, an update. Cancer Treat Rep 1982;9A:67–71.Google Scholar
  6. 6.
    Peckham MJ, Barrett A, Liew KH, et al. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cisplatin (BEP). Br J Cancer 1983;47:613–9.PubMedGoogle Scholar
  7. 7.
    Einhorn LH, Williams SD. Chemotherapy of disseminated seminoma. Cancer Clin Trials 1980;3:307–11.PubMedGoogle Scholar
  8. 8.
    Neijt JP, Ten Bokkel Huinink WW, Van der Burg MEL, et al. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5. Radiother Oncol 1984;2:19–29.PubMedGoogle Scholar
  9. 9.
    Wiltshaw E, Kroner T. Phase II study ofcis-dichlorodiammineplatinum in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55–60.PubMedGoogle Scholar
  10. 10.
    Neijt JP, Van der Burg MEL, Vriesendorp R, et al. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594–600.PubMedGoogle Scholar
  11. 11.
    Yagoda A. Chemotherapy of advanced urothelial tumours. Semin Urol 1983;1:60–74.PubMedGoogle Scholar
  12. 12.
    Denis L. Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet 1983;1:1378–9.Google Scholar
  13. 13.
    Slack NH. Results of chemotherapy protocols of the USA National Prostatic Cancer Project. Clin Oncol 1983;2:441–59.Google Scholar
  14. 14.
    Rossof AH, Talley RW, Stephans R, et al. Phase II evaluation ofcis-dichlorodiammineplatinum in advanced malignancies of the genito urinary and gynaecologic organs: a Southwest Oncology Group study. Cancer Treat Rep 1979;63:1557–64.PubMedGoogle Scholar
  15. 15.
    Hall DJ, Diasio R, Goplerund DR. Cis-platinum in gynaecologic cancer. II. Squamous cell carcinoma of the cervix. Am J Obstet Gynecol 1981;141:305–8.PubMedGoogle Scholar
  16. 16.
    Thigpen T, Shingleton H, Hansley H, Lagasse L, Blessing J. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899–903.PubMedGoogle Scholar
  17. 17.
    Muscato MS, Perry MC, Yarbro JW. Chemotherapy of cervical carcinoma. Semin Oncol 1982;9:373–87.PubMedGoogle Scholar
  18. 18.
    Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1982;59:225–8.PubMedGoogle Scholar
  19. 19.
    Newlands ES. New chemotherapeutic agents in the management of gestational trophoblastic disease. Semin Oncol 1982;9:239–43.PubMedGoogle Scholar
  20. 20.
    Hainsworth JD, Burnett LS, Jones HW, Greco FA. Resistant gestational choriocarcinoma: successful treatment with vinblastine, bleomycin and cisplatin. Cancer Treat Rep 1983;67:393–5.PubMedGoogle Scholar
  21. 21.
    Vriesendorp R, Aalders JG, Sleijfer DTh, Willemse PHB, Bouma J, Mulder NH. Treatment of malignant germ cell tumors of the ovary with cisplatin, vinblastine and bleomycin. Cancer Treat Rep 1984;68:779–81.PubMedGoogle Scholar
  22. 22.
    Hande KR, Des Prez RM. Chemotherapy and radiation therapy for non-small cell lung carcinoma. Clin Chest Med 1982;3:399–414.PubMedGoogle Scholar
  23. 23.
    Hoffman PC, Bitran JD, Golomb HM. Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol 1983;10:111–22.PubMedGoogle Scholar
  24. 24.
    Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981;95:414–20.PubMedGoogle Scholar
  25. 25.
    Kelsen D, Gralla R, Stoopler M, et al. Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. Cancer Treat Rep 1981;66:247–51.Google Scholar
  26. 26.
    Klastersky J, Longeval E, Nicaise C, Weerts D. Etoposide andcis-platinum in non-small-cell bronchogenic carcinoma. Cancer Treat Rev 1982;9:133–8.PubMedGoogle Scholar
  27. 27.
    Comis RL. Small cell carcinoma of the lung. Cancer Treat Rev 1982;9:237–58.PubMedGoogle Scholar
  28. 28.
    Cavelli F, Goldhirsch A, Siegenthaler P, Kaplan S, Beer M. Phase-II study withcis-dichlorodiammineplatinum in small cell anaplastic bronchogenic carcinoma. Eur. J Cancer 1980;16:617–21.PubMedGoogle Scholar
  29. 29.
    Srerocki JS, Hilares BS, Hopfan S, et al.cis-dichlorodiammineplatinum and VP 16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979;63:1593–7.PubMedGoogle Scholar
  30. 30.
    Kelsen D. Treatment of advanced esophageal cancer. Cancer 1982;50:2576–31.PubMedGoogle Scholar
  31. 31.
    Kelsen DP, Bains M, Hilaris B, et al. Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine and bleomycin. Cancer 1982;49:1174–7.PubMedGoogle Scholar
  32. 32.
    Beer M, Cocconi G, Ceci G, Varini M, Cavelli F. A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983;19:717–20.PubMedGoogle Scholar
  33. 33.
    Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius VK. Cisplatin: an active drug in the treatment of disseminated gastric cancer. Cancer 1984;53:18–22.PubMedGoogle Scholar
  34. 34.
    Moertel C, Fleming T, O'Connell M, Schutt A, Rubin J. A phase II trial of combined intensive course 5-FU, adriamycin andcis-platinum in advanced gastric and pancreatic carcinoma. Proc Am Soc Clin Oncol 1984;3:535.Google Scholar
  35. 35.
    Friedman MA. The use of intravenous cisplatin in various adult malignancies. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin: current status and new developments. New York: Academic Press, 1980:459–64.Google Scholar
  36. 36.
    Ajani J, Kantargian H, Kanojia M, Karlin D. Phase II trial ofcis-platin in advanced upper gastrointestinal cancer. Proc Am Soc Clin Oncol 1984;3:573.Google Scholar
  37. 37.
    Kolaric K, Roth A. Phase II clinical trial ofcis-dichlorodiammineplatinum for antitumorigenic activity fn previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;11:108–12.PubMedGoogle Scholar
  38. 38.
    Cavalli F, Jungi WF, Nissen NI, Pajak TF, Coleman M, Holland JF. Phase II trial ofcis-dichlorodiammineplatinum in advanced malignant lymphoma. Cancer 1981;48:1927–30.PubMedGoogle Scholar
  39. 39.
    Kroner T, Obrecht JP, Jungi WF. Etoposide as single agent and in combination withcis-platinum for malignant lymphomas. Cancer Treat Rev 1982;9A:39–43.Google Scholar
  40. 40.
    Von Heyden HW, Scherpe A, Nagel GA.Cis-dichlorodiammineplatinum and etoposide for patients with refractory lymphomas. Cancer Treat Rev 1982;9A:45–52.Google Scholar
  41. 41.
    Liepman MK, Wheeler RH, Zuckerman KS, Lobuglio AF. Combination chemotherapy of refractory lymphoma withcis-dichlorodiammineplatinum, vinblastine, and bleomycin. Cancer 1982;50:2736–9.PubMedGoogle Scholar
  42. 42.
    Broun GA, Petruska PJ, Hiramoto RN, Cohen HJ. Cisplatin, BCNU, cyclophosphamide and prednison in multiple myeloma. Cancer Treat Rep 1982;66:237–42.PubMedGoogle Scholar
  43. 43.
    Wittes RE, Cvitkovic E, Shah J, Gerold T, Strong EW.Cis-dichlorodiammineplatinum(11) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977;61:359–366.PubMedGoogle Scholar
  44. 44.
    Taylor SG. Head and neck cancer. In: Pinedo HM, Chabner BA, eds. Cancer Chemotherapy 1983. Amsterdam: Elsevier Science Publishers, 1983:291–306.Google Scholar
  45. 45.
    Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984;53:1819–24.PubMedGoogle Scholar
  46. 46.
    Jacobs C, Meyers F, Hendrickson C, Kohler M, Carter S. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. Cancer 1983;52:1563–9.PubMedGoogle Scholar
  47. 47.
    Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983;52:206–10.PubMedGoogle Scholar
  48. 48.
    Schaefer SD, Middleton R, Reisch J, Frenkel EP.Cis-platinum induction chemotherapy in the multimodality initial treatment of advanced stage IV carcinoma of the head and neck. Cancer 1983;51:2168–74.PubMedGoogle Scholar
  49. 49.
    Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy withcis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983;51:1353–5.PubMedGoogle Scholar
  50. 50.
    Aisner J, Wiernik PH. Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 1981;8:335–43.PubMedGoogle Scholar
  51. 51.
    Zidar BL, Pugh RP, Schiffer LM, et al. Treatment of six cases of mesothelioma with doxorubicin and cisplatin. Cancer 1983;52:1788–91.PubMedGoogle Scholar
  52. 52.
    Karakousis CP, Holtermann OA, Holyoke ED.Cis-dichlorodiammineplatinum in metastatic soft tissue sarcomas. Cancer Treat Rep 1979;63:2071–2.PubMedGoogle Scholar
  53. 53.
    Brenner J, Magill GB, Sordillo PP, Cheng EW, Yagoda A. Phase II trial of cisplatin in previously treated patients with advanced soft tissue sarcomas. Cancer 1982;50:2031–3.PubMedGoogle Scholar
  54. 54.
    Stephens R, Coltman C, Rossof A, et al.Cis-dichlorodiammineplatinum in adult patients: Southwest Oncology Group studies. Cancer Treat Rep 1979;63:1609–10.PubMedGoogle Scholar
  55. 55.
    Ochs JJ, Freeman AI, Douglass HO, Higby DS, Mindell ER, Sinks LF.Cis-dichlorodiammineplatinum in advanced osteogenic sarcoma. Cancer Treat Rep 1978;62:239–45.PubMedGoogle Scholar
  56. 56.
    Ettinger LJ, Douglass HO, Higby DS, et al. Adjuvant adriamycin andcis-diamminedichloroplatinum in primary osteosarcoma. Cancer 1981;47:248–54.PubMedGoogle Scholar
  57. 57.
    Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor withcis-diamminedichloroplatinum. Cancer 1983;51:402–7.PubMedGoogle Scholar
  58. 58.
    Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma. Cancer Treat Rep 1982;66:31–5.PubMedGoogle Scholar
  59. 59.
    York RM, Lawson DH, McKay J. Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin. Cancer 1983;52:2220–2.PubMedGoogle Scholar
  60. 60.
    Nathanson L, Kaufman SD, Carey RW. Vinblastine, infusion bleomycin andcis-dichlorodiammineplatinum chemotherapy in metastatic melanoma. Cancer 1981;48:1290–4.PubMedGoogle Scholar
  61. 61.
    Khan AB, D'Souza BJ, Wharam MD, et al. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 1982;66:2013–20.PubMedGoogle Scholar
  62. 62.
    Howell SB, Pfeifle CE, Wung WE, Olshen RA. Intraperitonealcis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 1983;43:1426–31.PubMedGoogle Scholar
  63. 63.
    Stark JJ, Howell SB. Nephrotoxicity ofcis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 1978;23:461–6.PubMedGoogle Scholar
  64. 64.
    Ten Bokkel Huinink WW, Hoefnagel C, Simonetti G, et al. A simple radioisotope technique for assessment of acute drug induced nephrotoxicity. Proc Am Soc Clin Oncol 1981;17:349.Google Scholar
  65. 65.
    Elwood CM, Sigman EM. The measurement of glomerular filtration rate and effective renal plasma flow in man by iothalamate125I and iodosyracet131. Circulation 1967;36:441–8.PubMedGoogle Scholar
  66. 66.
    Levinsky NG, Levy M. Clearance techniques. In: Orloff J, Berliner RW, eds. Handbook of Physiology. Sect. 8. Renal Physiology. Washington DC: American Physiological Society, 1973.Google Scholar
  67. 67.
    Donker AJM, Van der Hem GK, Sluiter WJ, et al. A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 1977;20:97–103.PubMedGoogle Scholar
  68. 68.
    Meijer S, Offerman JJG, Sleijfer DTh, et al. Acute effects of infusion ofcis-diamminedichloroplatinum (CDDP) on renal function. In: Hacker MP, Douple EB, Krakoff IH, eds. Platinum coordination complexes in cancer chemotherapy. Boston: Martinus Nijhoff Publishers, 1984:203.Google Scholar
  69. 69.
    Offerman JJG, Meijer S, Sleijfer DTh, et al. Acute effects ofcis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 1984;12:36–8.PubMedGoogle Scholar
  70. 70.
    Meijer S, Sleijfer DTh, Mulder NH, et al. Some effects of combination chemotherapy withcis-platinum on renal function in patients with non seminomatous testicular carcinoma. Cancer 1983;51:2035–40.PubMedGoogle Scholar
  71. 71.
    Dentino ME, Luft FC, Yum MN, et al. Long-term effects ofcis-diamminedichloroplatinum (CDDP) on renal function and structure in man. Cancer 1978;41:1274–81.PubMedGoogle Scholar
  72. 72.
    Jones BR, Bhalla RB, Mladek J, et al. Comparison of methods of evaluating nephrotoxicity ofcis-platinum. Clin Pharmacol Ther 1980;27:557–62.PubMedGoogle Scholar
  73. 73.
    Flemming JJ, Collis C, Peckham MJ. Renal damage aftercis-platinum. Lancet 1979;2:961.Google Scholar
  74. 74.
    Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90:929–31.PubMedGoogle Scholar
  75. 75.
    Blachley MD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981;95:628–32.PubMedGoogle Scholar
  76. 76.
    Bitran JD, Debser RK, Billings AA, et al. Acute nephrotoxicity followingcis-dichlorodiammineplatinum. Cancer 1982;49:1784–8.PubMedGoogle Scholar
  77. 77.
    Hardaker WT, Stone RA, McCoy R. Platinum nephrotoxicity. Cancer 1974;34:1030–2.PubMedGoogle Scholar
  78. 78.
    Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. Pathology in clinical trials ofcis-platinum(II)diamminedichloride. Cancer 1977;39:1362–71.PubMedGoogle Scholar
  79. 79.
    Hayes DM, Cvitkovic E, Golbey RB, et al. High dosecis-platinumdiamminedichloride. Cancer 1977;39:1372–81.PubMedGoogle Scholar
  80. 80.
    Meijer S, Mulder NH, Sleijfer DTh, et al. Nephrotoxicity ofcis-diamminedichlorideplatinum (CDDP) during remission-induction and maintenance chemotherapy of testicular carcinoma. Cancer Chemother Pharmacol 1982;8:27–30.PubMedGoogle Scholar
  81. 81.
    Meijer S, Mulder NH, Sleijfer DTh, et al. Influence of combination chemotherapy withcis-diamminedichloroplatinum on renal function: long-term effects. Oncology 1983;40:170–3.PubMedGoogle Scholar
  82. 82.
    Aggarwal SK, Whitehouse MW, Ramachandran C. Ultrastructural effects of cisplatin. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin, current status and new developments. New York: Academic Press, 1980:79–111.Google Scholar
  83. 83.
    Choie DD, Longnecker DS, Del Campo AA. Acute and chronic cisplatin nephropathy in rats. Lab Invest 1981;44:397–402.PubMedGoogle Scholar
  84. 84.
    Offerman JJG, Sleijfer DTh, Mulder NH, et al. The effect of captopril on renal function in patients during the firstcis-diamminedichloroplatinum II infusion. Cancer Chemother Pharmacol 1985;14:262–4.PubMedGoogle Scholar
  85. 85.
    Offerman JJG, Mulder NH, Sleijfer DTh. et al. Influence of captopril oncis-diamminedichloroplatinum induced renal toxicity. Am J Nephrol (in press).Google Scholar
  86. 86.
    Offerman JJG, Meijer S, Sleijfer DTh, et al. Calcium entry blockade with verapamil in cisplatin-treated patients. Clin Nephrol (in press).Google Scholar
  87. 87.
    Ross AD, Gale GR. Reduction of the renal toxicity ofcis-dichlorodiammineplatinum(II) by probenecid. Cancer Treat Rep 1979;63:781–7.PubMedGoogle Scholar
  88. 88.
    Daley-Yates PT, McBrien DC. Enhancement of cisplatin nephrotoxicity by probenecid. Cancer Rep 1984;68:445–6.Google Scholar
  89. 89.
    Speer RJ, Ridgweay H, Hall LM, et al. Co-ordination complexes of platinum as antitumor agents. Cancer Chemother Rep 1975;59:629–41.PubMedGoogle Scholar
  90. 90.
    Slater TF, Ahmed J, Ibrahim SA. Studies on the nephrotoxicity ofcis-dichlorodiammineplatinum and related substances. J Clin Hematol Oncol 1977;7:534–47.Google Scholar
  91. 91.
    Higby DJ, Wallace Jr HJ, Bekesi JG. Reduction ofcis-dichlorodiammineplatinum II (DDP) toxicity by penicillamine (Pn) compounds in animal models and humans. Proc Am Assoc Cancer Res 1975;16:131.Google Scholar
  92. 92.
    Howell SB, Taetle R. Effect of sodium thiosulfate oncis-dichlorodiammineplatinum(II) toxicity and antitumor acitivity in L 1210 leukemia. Cancer Treat Rep 1980;64:611–6.PubMedGoogle Scholar
  93. 93.
    Hayes FA, Green AA, Senzer N, et al. Tetany: A complication ofcis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep 1979;63:547–8.PubMedGoogle Scholar
  94. 94.
    Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. Acute renal failure aftercis-dichlorodiammineplatinum(II) and gentamycin-cephalothin therapies. Cancer Treat Rep 1978;62:693–8.PubMedGoogle Scholar
  95. 95.
    Salem PA, Jabboury KW, Khalik KMF. Severe nephrotoxicity: a probable complication ofcis-dichlorodiammineplatinum(II) and cephalotin-gentamycin therapy. Oncology 1982;39:31–2.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1985

Authors and Affiliations

  • Dirk Th. Sleijfer
    • 1
  • Sijtze Meijer
    • 2
  • Nanno H. Mulder
    • 1
  1. 1.Department of Medical OncologyUniversity Hospital GroningenEZ GroningenThe Netherlands
  2. 2.Department of NephrologyUniversity Hospital GroningenEZ GroningenThe Netherlands

Personalised recommendations